TradeLegend
2021-11-20
🤑
Bristol Myers Stock Keeps Skidding on FDA Heart Drug Review
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
2
5
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":872026671,"tweetId":"872026671","gmtCreate":1637378019821,"gmtModify":1637378019993,"author":{"id":3565930395680990,"idStr":"3565930395680990","authorId":3565930395680990,"authorIdStr":"3565930395680990","name":"TradeLegend","avatar":"https://static.tigerbbs.com/efcf72a8fc8d429f1da25c34e3db472a","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":10,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>🤑</p></body></html>","htmlText":"<html><head></head><body><p>🤑</p></body></html>","text":"🤑","highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/872026671","repostId":1111549440,"repostType":4,"repost":{"id":"1111549440","kind":"news","pubTimestamp":1637372002,"share":"https://www.laohu8.com/m/news/1111549440?lang=&edition=full","pubTime":"2021-11-20 09:33","market":"us","language":"en","title":"Bristol Myers Stock Keeps Skidding on FDA Heart Drug Review","url":"https://stock-news.laohu8.com/highlight/detail?id=1111549440","media":"The Street","summary":"$Bristol Myers Squibb (BMY)$ shares fell Friday after the pharmaceutical titan said the FDA has exte","content":"<p>$Bristol Myers Squibb (<b>BMY</b>)$ shares fell Friday after the pharmaceutical titan said the FDA has extended its review of heart drug mavacamten for three months, until April 28.</p>\n<p>The drug treats symptomatic obstructive hypertrophic cardiomyopathy (oHCM).</p>\n<p>The Food and Drug Administration notified Bristol Thursday of the extension “to allow sufficient time to review information pertaining to updates to the proposed Risk Evaluation Mitigation Strategy (REMS),” the company said.</p>\n<p>“A REMS program was included in the initial application for mavacamten. No additional data or studies have been requested.”</p>\n<p>Bristol Myers recently traded at $58.07, down 1.6%. It has slid 14% over the past three months.</p>\n<p>“We are confident in the profile of mavacamten,” said Samit Hirawat, chief medical officer, global drug development at Bristol Myers.</p>\n<p>“This first-in-class cardiac myosin inhibitor demonstrated clinically meaningful improvements in symptoms, functional status, and quality of life in symptomatic oHCM patients in the pivotal EXPLORER-HCM trial.”</p>\n<p>Mavacamten represented the top potential drug of MyoKardia, which Bristol Myers acquired last year for $13.1 billion, MarketWatch reports.</p>\n<p>Morningstar analyst Damien Conover puts fair value for Bristol Myers at $68.</p>\n<p>“Bristol Myers hosted an investor day highlighting a strong pipeline that holds the potential to offset the firm’s major patent losses over the next decade, a key element supporting our wide moat rating,” he wrote in a commentary Tuesday.</p>\n<p>“With most of the updates focused on still risky early-stage pipeline assets, the updates didn’t move our fair value estimate. However, we continue to view the stock as undervalued with the market not fully appreciating the firm’s late-stage pipeline.”</p>","source":"lsy1610613172068","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bristol Myers Stock Keeps Skidding on FDA Heart Drug Review</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBristol Myers Stock Keeps Skidding on FDA Heart Drug Review\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-20 09:33 GMT+8 <a href=https://www.thestreet.com/investing/bristol-myers-heart-drug-mavacamten-gets-extended-fda-review><strong>The Street</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>$Bristol Myers Squibb (BMY)$ shares fell Friday after the pharmaceutical titan said the FDA has extended its review of heart drug mavacamten for three months, until April 28.\nThe drug treats ...</p>\n\n<a href=\"https://www.thestreet.com/investing/bristol-myers-heart-drug-mavacamten-gets-extended-fda-review\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BMY":"施贵宝"},"source_url":"https://www.thestreet.com/investing/bristol-myers-heart-drug-mavacamten-gets-extended-fda-review","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1111549440","content_text":"$Bristol Myers Squibb (BMY)$ shares fell Friday after the pharmaceutical titan said the FDA has extended its review of heart drug mavacamten for three months, until April 28.\nThe drug treats symptomatic obstructive hypertrophic cardiomyopathy (oHCM).\nThe Food and Drug Administration notified Bristol Thursday of the extension “to allow sufficient time to review information pertaining to updates to the proposed Risk Evaluation Mitigation Strategy (REMS),” the company said.\n“A REMS program was included in the initial application for mavacamten. No additional data or studies have been requested.”\nBristol Myers recently traded at $58.07, down 1.6%. It has slid 14% over the past three months.\n“We are confident in the profile of mavacamten,” said Samit Hirawat, chief medical officer, global drug development at Bristol Myers.\n“This first-in-class cardiac myosin inhibitor demonstrated clinically meaningful improvements in symptoms, functional status, and quality of life in symptomatic oHCM patients in the pivotal EXPLORER-HCM trial.”\nMavacamten represented the top potential drug of MyoKardia, which Bristol Myers acquired last year for $13.1 billion, MarketWatch reports.\nMorningstar analyst Damien Conover puts fair value for Bristol Myers at $68.\n“Bristol Myers hosted an investor day highlighting a strong pipeline that holds the potential to offset the firm’s major patent losses over the next decade, a key element supporting our wide moat rating,” he wrote in a commentary Tuesday.\n“With most of the updates focused on still risky early-stage pipeline assets, the updates didn’t move our fair value estimate. However, we continue to view the stock as undervalued with the market not fully appreciating the firm’s late-stage pipeline.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":167,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/872026671"}
精彩评论